A Phase II, Prospective, Open-label, Single Arm Study of the Efficacy and Safety of Concurrent Conventional TACE and Sorafenib in Patients With Hepatocellular Carcinoma and Extrahepatic Metastasis (COTSOM Study)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms COTSOM
- 15 Dec 2017 Planned End Date changed from 1 Jun 2016 to 1 Jun 2018.
- 15 Dec 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
- 15 Dec 2017 Status changed from recruiting to active, no longer recruiting.